Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
nervous system diseases | D009422 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
vyvgart | Biologic Licensing Application | 2025-01-16 |
vyvgart hytrulo | Biologic Licensing Application | 2024-08-14 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
extravasation of diagnostic and therapeutic materials | — | D005119 | — |
Expiration | Code | ||
---|---|---|---|
efgartigimod alfa / hyaluronidase, Vyvgart Hytrulo, Argenx BV | |||
2030-06-20 | Orphan excl. | ||
efgartigimod alfa, Vyvgart, Argenx BV | |||
2028-12-17 | Orphan excl. |
Code | Description |
---|---|
J9332 | Injection, efgartigimod alfa-fcab, 2mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | 4 | 11 | 3 | 3 | 18 |
Muscle weakness | D018908 | — | — | — | 4 | 10 | 2 | 1 | 14 |
Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | 2 | — | 1 | 1 | 4 |
Chronic inflammatory demyelinating polyradiculoneuropathy | D020277 | EFO_1000868 | G61.81 | — | 2 | — | 1 | 1 | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 1 | 6 | — | — | 7 |
Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | 6 | — | — | 7 |
Paresis | D010291 | — | — | — | 1 | 2 | — | — | 3 |
Pemphigus | D010392 | EFO_1000749 | L10 | — | 1 | 2 | — | — | 3 |
Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | 2 | 1 | — | — | 3 |
Bullous pemphigoid | D010391 | EFO_0007187 | L12 | — | 1 | 2 | — | — | 2 |
Myositis | D009220 | EFO_0000783 | G72.49 | — | 1 | 2 | — | — | 2 |
Dermatomyositis | D003882 | EFO_0000398 | M33 | — | 1 | 2 | — | — | 2 |
Muscular diseases | D009135 | EFO_0002970 | G72.9 | — | 1 | 2 | — | — | 2 |
Polymyositis | D017285 | EFO_0003063 | M33.2 | — | 1 | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Syndrome | D013577 | — | — | — | 5 | — | — | — | 5 |
Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | — | 2 | — | — | — | 2 |
Tachycardia | D013610 | — | R00.0 | — | 2 | — | — | — | 2 |
Guillain-barre syndrome | D020275 | EFO_0007292 | G61.0 | — | 1 | — | — | — | 1 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | — | 1 |
Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | 1 | — | — | — | 1 |
Lupus nephritis | D008181 | EFO_0005761 | — | — | 1 | — | — | — | 1 |
Nephritis | D009393 | — | N05 | — | 1 | — | — | — | 1 |
Neuritis | D009443 | — | — | — | 1 | — | — | — | 1 |
Optic neuritis | D009902 | EFO_0007405 | H46 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Drug common name | Efgartigimod alfa |
INN | efgartigimod alfa |
Description | Efgartigimod alfa, sold under the brand name Vyvgart, is a medication used to treat myasthenia gravis. Efgartigimod alfa is a neonatal Fc receptor blocker and is a new class of medication. It is an antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing FcRn from recycling immunoglobulin G (IgG) back into the blood. The medication causes a reduction in overall levels of IgG, including the abnormal acetylcholine receptor (AChR) antibodies that are present in myasthenia gravis. It is also available coformulated with hyaluronidase.
|
Classification | Protein |
Drug class | Fc fusion protein; immunomodulators |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 1821402-21-4 |
RxCUI | — |
ChEMBL ID | CHEMBL4297551 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB15270 |
UNII ID | 961YV2O515 (ChemIDplus, GSRS) |